© 2020 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2020 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
October 30, 2020
Here are the top 5 biosimilar articles for the week of October 26, 2020.
October 29, 2020
October 28, 2020
Opposing interests make it hard to define what elements are essential for a competitive marketplace.
October 27, 2020
Chad Pettit, MBA, executive director of marketing and team leader for global biosimilar launches at Amgen, discussed Amgen’s recent report on the state of the US biosimilars marketplace.
The strong growth of biosimilars Pfizer recently launched in the United States are part of the success story, although reference etanercept (Enbrel) sales have seen major erosion.
With a sizeable round of fresh capital, Alvotech hopes to bring monoclonal antibodies and fusion proteins through the development pipeline.
October 26, 2020
A study of mandatory switching for patients with rheumatologic conditions led to savings without effect on safety or efficacy.
A trio of legal experts discuss Amy Coney Barrett's bid for a Supreme Court seat and how that might affect deliberations on the Affordable Care Act and the Biologics Price Competition and Innovation Act (BPCIA).
A retrospective analysis of data from the US Veterans Affairs Healthcare System database provides positive switching data for infliximab products.
October 25, 2020
We spoke with Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs, for her take on requirements for comparative efficacy trails and whether they add meaningful data for the purposes of biosimilar acceptance.
October 24, 2020
Deana Ferreri, PhD
European investigators have derived a set of core principals for developing higher utilization of biosimilars.
October 23, 2020
Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.